Skip to content

FMT for inflammatory bowel disease: ulcerative colitis and Crohn's

Living with ulcerative colitis or Crohn's disease often means years of flares, steroid courses and medicine changes. Of all the conditions studied beyond C. difficile infection, ulcerative colitis has the strongest evidence for fecal microbiota transplant (FMT). This page explains what the trials found, what guidelines say, and how FMT is used as supportive care alongside your gastroenterologist's treatment at Resplice Institute in Hyderabad and Mumbai.

Illustration of the colon in inflammatory bowel disease receiving donor microbiotaA large intestine with an inflamed lower section, as in ulcerative colitis, with a dish of donor gut bacteria being delivered.Donor microbiotaInflamedlining

Evidence level 4 of 5

Multiple randomised trials and meta-analyses. See the studies

Does FMT work for ulcerative colitis?

For some people, yes. In three placebo-controlled trials, 24–32% of patients with active ulcerative colitis reached remission after donor FMT, compared with 5–9% in the control groups, and a 2023 Cochrane review concluded that FMT may increase remission rates. It is not a cure, long-term data are limited, and the evidence for Crohn's disease is still very uncertain.

Key points

  • Later trials pooled several donors and processed stool without oxygen, approaches designed to improve results.
  • Earlier may be better: in one trial, three of four people diagnosed within a year went into remission.
  • Keeping remission is the open question; an Indian pilot study suggests repeat FMT every eight weeks may help.
  • The 2024 AGA guideline suggests using conventional FMT for IBD within clinical trials.
  • FMT is supportive care: it never replaces mesalamine, steroids, immunomodulators or biologics.

What is fecal microbiota transplant (FMT)?

Fecal microbiota transplant (FMT), also called faecal microbiota transplantation or a stool transplant, moves a complete community of gut bacteria from a carefully screened, healthy donor into a patient’s bowel. The aim is to rebuild a balanced gut microbiome. It is usually given by colonoscopy or enema; some research studies use capsules.

FMT is an established treatment for recurrent C. difficile infection, where gastroenterology guidelines recommend it for suitable adults.2 For ulcerative colitis it is supported by randomised trials, but it is not yet standard care.

FMT for IBD at a glance

StatusSupported by randomised trials in ulcerative colitis; not yet standard care.
Strongest human evidenceCochrane review of 10 studies with 468 participants.1
What changed24–32% remission with donor FMT against 5–9% in control groups, in active ulcerative colitis.
Biggest uncertaintyThe best way to keep people in remission; Crohn’s disease evidence is very uncertain.
Standard careMesalamine, steroids, immunomodulators and biologics, guided by your gastroenterologist.
Where FMT fitsSupportive care alongside standard treatment, after specialist assessment, with written consent and monitoring.

Why does the gut microbiome matter in IBD?

People with IBD usually have a less diverse gut microbiome, with fewer of the bacteria that calm inflammation. FMT tries to restore that missing diversity.

These findings shape how we select donors, prepare material and decide who is most likely to respond.

Healthy and inflamed bowel lining comparedSide-by-side cross-sections of the bowel lining: the healthy side has varied microbes, a thick mucus layer and intact cells; the inflamed side has fewer microbe types, a thin mucus layer, an ulcer and immune cells.Healthy liningVaried microbes, thick mucus, intact cellsInflamed lining (colitis)Fewer types of microbe, ulcer, immune cells
In ulcerative colitis the lining is inflamed and the microbiome is usually less varied.
  • Diversity returnsIn the first placebo-controlled trial, patients given FMT showed greater microbial diversity in their stool than those given placebo.3
  • Donor and preparation matterSeven of nine remissions in that trial came from a single donor, and later trials pooled donors and processed stool without oxygen, approaches designed to improve results.34
  • Earlier may be betterThree of four patients who had ulcerative colitis for a year or less went into remission, compared with six of 34 with longer-standing disease.3

How common is IBD in India?

A burden analysis of six countries estimated about 1.4 million people with IBD in India in 2010, second only to the United States at 1.6 million.5 Indian gastroenterologists have also contributed some of the world’s FMT research in ulcerative colitis, including a randomised maintenance study from Ludhiana.7

Estimated number of people with IBD in 2010: United States and IndiaBar chart: about 1.6 million people with IBD in the United States and 1.4 million in India, 2010 estimates.United StatesUnited States: about 1.6 million people with IBD (2010 estimate)1.6 millionIndiaIndia: about 1.4 million people with IBD (2010 estimate)1.4 million
Estimated people living with IBD, 2010. Burden analysis of six countries.5
1.4 million
people with IBD in India (2010 estimate)5
2nd
highest IBD burden of six countries analysed, after the US5
24–32%
remission with donor FMT in three UC trials364

What does the research say about FMT for IBD?

For ulcerative colitis, FMT reaches the fourth step of our evidence ladder. For Crohn’s disease, the evidence is much thinner.

  1. 5Guideline-recommended careRecurrent C. difficile
  2. 4Multiple randomised trials and meta-analysesIBD evidence is here
  3. 3Small randomised trials
  4. 2Case reports and small studies
  5. 1Laboratory and animal research

Level 5 shows where fully proven FMT sits today, for comparison.

Level 5

Guideline-recommended care

Guidelines still advise FMT for IBD mainly within clinical trials

The 2024 AGA guideline recommends FMT for recurrent C. difficile infection, but suggests against conventional FMT for IBD outside clinical trials.2

  • Clinical guideline
  • Not yet standard
Level 4

Multiple randomised trials and meta-analyses

Cochrane review: FMT may increase remission in ulcerative colitis

Pooling 10 studies with 468 participants, reviewers found FMT may increase clinical remission in UC (risk ratio 1.79). Evidence for Crohn’s disease and for keeping UC in remission was very uncertain.1

  • Meta-analysis
  • Benefit in UC
Level 3

Small randomised trials

Weekly FMT enemas: 24% remission against 5% on placebo

The first placebo-controlled trial in active ulcerative colitis treated 75 patients with six weekly enemas.3

  • Randomised trial
  • Benefit seen

Intensive multi-donor FMT: 27% against 8%

Patients received colonoscopic FMT then enemas five days a week for eight weeks, each made from three to seven donors.6

  • Randomised trial
  • Benefit seen

One-week anaerobic FMT: 32% steroid-free remission against 9%

Pooled donor stool processed without oxygen was given just three times over one week.4

  • Randomised trial
  • Benefit seen

Indian maintenance study: FMT every eight weeks for a year

In 61 patients already in remission, the Ludhiana team concluded that maintenance FMT may help sustain clinical, endoscopic and histological remission.7

  • Randomised pilot trial
  • Promising
Level 2

Case reports and small studies

Many uncontrolled case series exist; the randomised trials above now carry more weight.

Level 1

Laboratory and animal research

A large body of laboratory and animal research underpins these trials.

What the researchers concluded

“Anaerobically prepared fecal microbiota transplantation may be effective in treating ulcerative colitis”

Costello et al., JAMA, 20194

“…induces clinical remission and endoscopic improvement in active ulcerative colitis”

Paramsothy et al., Lancet, 20176

Our reading of the evidence

The evidence in ulcerative colitis is real but modest: roughly a quarter to a third of patients respond, protocols vary widely, and the best way to keep people in remission is still being worked out. International guidelines still advise using FMT for IBD within structured protocols. At Resplice, FMT for IBD is provided only as supportive care, alongside and never instead of your gastroenterologist’s treatment, after specialist assessment, with written informed consent and close monitoring.

Published case reports: FMT for IBD

These trials were run by independent research teams and published in peer-reviewed journals. The patients are not Resplice patients.

73 adults with mild to moderate ulcerative colitis in Australia

Published case: Costello SP, JAMA, 2019

Patients
Adults with mild to moderately active ulcerative colitis, randomised to donor FMT (38) or their own stool (35).
Treatment
Pooled donor stool processed without oxygen, given once by colonoscopy and then by two enemas over one week.
What changed
32% (12 of 38) reached steroid-free remission at eight weeks against 9% (3 of 35). Five of the 12 were still in remission at 12 months.
What it can't tell us
Follow-up at 12 months was incomplete, and serious side effects occurred in both groups (three with donor FMT, two with their own stool).

61 Indian patients: can maintenance FMT keep colitis quiet?

Published case: Sood A, J Crohns Colitis, 2019

Patients
People with ulcerative colitis treated at Dayanand Medical College, Ludhiana, who had reached clinical remission after several FMT sessions.
Treatment
Randomised to FMT (31) or placebo (30) by colonoscopy every eight weeks for 48 weeks, while continuing standard therapy.
What changed
The authors concluded that maintenance FMT may help sustain clinical, endoscopic and histological remission.
What it can't tell us
A pilot study that needs confirming in larger trials.

Who might FMT be suitable for?

May be appropriate if

  • You have mild to moderate ulcerative colitis that is not well controlled on current treatment
  • You depend on steroids and want, with your gastroenterologist, to reduce them
  • You have IBD with recurrent C. difficile infection, where FMT is strongly supported
  • You have Crohn's disease or pouchitis and want to discuss FMT case by case, knowing the evidence is limited

Not advised if

  • You have acute severe colitis (frequent bloody diarrhoea, fever, a fast heart rate): this needs hospital care now
  • Your immune system is severely weakened
  • There is any suspicion of toxic megacolon or bowel perforation
  • You plan to stop your IBD medicines: FMT is supportive care, not a replacement

What happens at an FMT assessment at Resplice?

Nobody is booked straight in for FMT. A typical pathway has five steps, and you can stop at any point. Your existing doctors are kept informed throughout.

  1. Initial assessment

    We review your diagnosis, disease extent, colonoscopy and biopsy reports, current treatment and flare history with you.

  2. Gut health evaluation

    Blood and stool tests look for infections, inflammation or other problems that need treating first, and help decide whether FMT is appropriate at all.

  3. Microbiome testing and treatment planning

    Microbiome testing and stool markers of inflammation set your baseline. You receive a written plan covering the route, number of sessions, how we will measure response and when to review.

  4. FMT procedure

    Screened donor microbiota from our stool bank is usually given by colonoscopy, retention enema or both, as in the published trials.

  5. Follow-up and long-term monitoring

    We track symptoms, stool inflammation markers and, where needed, endoscopy, and coordinate any medicine changes with your gastroenterologist.

Is FMT safe? Side effects and donor screening

From donor to gut: how FMT works
  1. Healthy donor

    A healthy adult volunteer offers to donate.

  2. Screening

    Health questionnaire plus blood and stool tests.

  3. Stool bank

    Approved samples are processed and stored.

  4. Preparation

    Prepared under laboratory conditions.

  5. Delivery

    Given by colonoscopy, enema or another route.

  6. Engraftment

    Donor microbes settle and grow in the gut.

FMT is generally well tolerated when donors are carefully screened. The most common effects are short-lived bloating, cramps, loose stools or a mild fever. Rare but serious infections have been reported worldwide when donor screening was inadequate, which is why screening matters more than any other step.

People with severely weakened immune systems face higher risks, so your own health is reviewed in detail before FMT is considered, and the benefits, risks and alternatives are explained before you give written consent.

International donor-screening standards include

  • A detailed health, travel and lifestyle questionnaire for every donor
  • Blood tests for infections such as HIV, hepatitis and syphilis
  • Stool tests for C. difficile, disease-causing bacteria, parasites and drug-resistant organisms
  • Repeat testing over time, so that every batch can be traced from donor to patient

Resplice Institute’s FMT service in Hyderabad and Mumbai

Services

Clinical gut-health assessment, microbiome testing, FMT for recognised indications, post-treatment monitoring, and nutrition and lifestyle guidance.

Donor material

Supplied from Resplice Institute's stool bank. Our donor-screening protocol is available on request.

Locations

Hyderabad (Manikonda and Patancheru, Telangana) and Mumbai, Maharashtra.

Charges

Fees depend on the tests and treatment plan, and are given to you in writing before any treatment.

Questions to ask before you consider FMT

Whether you come to us or go elsewhere, these are fair questions to put to any FMT provider. A good clinic will welcome them.

  • Why do you think FMT is appropriate for me, and what is the evidence for my condition?
  • Is this a recognised indication for FMT, or part of an ethics-committee-approved study?
  • How are donors screened, and can I see your screening protocol?
  • Which route will you use, how many sessions will I need, and how do I prepare?
  • Which side effects should I watch for, and who do I call if I feel unwell afterwards?
  • How will we measure whether it has helped, and when?
  • Should any of my current medicines change? (Never stop a medicine on your own.)
  • What is the total cost, including tests and follow-up visits?

Frequently asked questions about FMT for IBD and ulcerative colitis

What is the success rate of FMT for ulcerative colitis?

In three placebo-controlled trials, 24–32% of patients with active ulcerative colitis reached remission with donor FMT, compared with 5–9% in the control groups. Response depends on the protocol, the donor and the individual.

Does FMT work for Crohn's disease?

The evidence is very uncertain. A 2023 Cochrane review could not confirm a benefit for Crohn’s disease, so we only consider FMT case by case and explain the limits clearly.

How many FMT sessions are needed for ulcerative colitis?

Trial protocols ranged from three treatments over one week to enemas five days a week for eight weeks, and maintenance sessions every eight weeks. Your plan is set after assessment.

Can FMT cause a flare?

Some patients in trials had worsening symptoms, and in one major trial serious side effects occurred at similar rates with donor FMT and placebo. We monitor closely after each session and act early if symptoms worsen.

Should I stop mesalamine, steroids or biologics before FMT?

No. Keep taking your IBD medicines unless your gastroenterologist advises otherwise. In the trials, patients continued standard therapy, and steroids were reduced only under medical supervision.

Is FMT approved for IBD?

FMT is guideline-recommended for recurrent C. difficile infection, including in people with IBD. For IBD itself, the 2024 AGA guideline suggests using conventional FMT within clinical trials, which is why it is provided only as carefully monitored supportive care, with informed consent.

Who are stool donors and how are they screened?

Donors are healthy adult volunteers. Under international screening standards, each donor completes a detailed health questionnaire and passes blood and stool tests for infections and drug-resistant bacteria, with testing repeated over time. You are entitled to ask any FMT provider, including us, to explain their donor-screening protocol before treatment.

Where are Resplice Institute's FMT centres?

Resplice Institute’s gut microbiome and FMT service is available in two cities: Hyderabad, at our Manikonda and Patancheru centres in Telangana, and Mumbai, Maharashtra. Assessments, microbiome testing and follow-up can be arranged in either city.

How much does FMT cost in Hyderabad and Mumbai?

Cost depends on the tests you need, the delivery route and the number of sessions in your plan. We give you a written estimate after the first consultation, before any treatment begins.

Contact and appointments

For an appointment, please bring your colonoscopy and biopsy reports, recent blood and stool tests and a list of current medicines.

Appointment enquiries Call +91 80473 61350 Centres in Hyderabad and Mumbai

Our FMT centres

Hyderabad: Manikonda

Vaishnavione, 3rd Floor, above Vijetha Supermarket, Shivapuri Colony, Manikonda, Hyderabad, Telangana 500089

Hyderabad: Patancheru

RM/6 5-98, beside Rainbow Meadows, Krishna Reddy Pet, Patelguda, Patancheru, Telangana 502319

Mumbai

[Full clinic address and PIN code]
Mumbai, Maharashtra

References

  1. Imdad A, et al. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2023;4:CD012774. doi.org/10.1002/14651858.CD012774.pub3
  2. Peery AF, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409–434. doi.org/10.1053/j.gastro.2024.01.008
  3. Moayyedi P, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102–109. doi.org/10.1053/j.gastro.2015.04.001
  4. Costello SP, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321(2):156–164. doi.org/10.1001/jama.2018.20046
  5. Singh P, Ananthakrishnan A, Ahuja V. Pivot to Asia: inflammatory bowel disease burden. Intest Res. 2017;15(1):138–141. doi.org/10.5217/ir.2017.15.1.138
  6. Paramsothy S, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228. pubmed.ncbi.nlm.nih.gov/28214091/
  7. Sood A, et al. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019;13(10):1311–1317. doi.org/10.1093/ecco-jcc/jjz060
Call Now Button